Carboplatin: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Carboplatin. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Leukopenia | 98% |
| Nausea and vomiting | 98% |
| Neutropenia | 97% |
| Vomiting | 97% |
| Anemia | 91% |
| Magnesium | 88% |
| <1,000 cells/mm | 81% |
| Thrombocytopenia | 70% |
| <2,000 cells/mm | 68% |
| Other gi side effects | 62% |
| Transfusions | 42% |
| Peripheral neuropathies | 42% |
| <50,000/mm | 41% |
| Central neurotoxicity | 40% |
| Asthenia | 40% |
| Pain | 37% |
| Ototoxicity | 33% |
| Blood urea elevations | 31% |
| Alkaline phosphatase elevations | 29% |
| Potassium | 22% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin, USP vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously trea…
Medical disclaimer: Always consult a qualified healthcare professional about any medication.